WO2011026206A1 - SEQÜÊNCIA DE ÁCIDO NUCLÉICO ISOLADA, VETOR DE EXPRESSÃO, COMPOSIÇÃO IMUNOGÊNICA SINÉRGICA QUE COMPREENDE UM VETOR DE EXPRESSÃO QUE CODIFICA A PROTEÍNA E7 DO VÍRUS DO PAPILOMA HUMANO (HPV) FUSIONADA À PROTEÍNA gD DO VÍRUS HERPES HUMANO TIPO 1 (HSV-1) E UM VETOR DE EXPRESSÃO QUE CODIFICA UMA CITOCINA E SEUS USOS - Google Patents
SEQÜÊNCIA DE ÁCIDO NUCLÉICO ISOLADA, VETOR DE EXPRESSÃO, COMPOSIÇÃO IMUNOGÊNICA SINÉRGICA QUE COMPREENDE UM VETOR DE EXPRESSÃO QUE CODIFICA A PROTEÍNA E7 DO VÍRUS DO PAPILOMA HUMANO (HPV) FUSIONADA À PROTEÍNA gD DO VÍRUS HERPES HUMANO TIPO 1 (HSV-1) E UM VETOR DE EXPRESSÃO QUE CODIFICA UMA CITOCINA E SEUS USOS Download PDFInfo
- Publication number
- WO2011026206A1 WO2011026206A1 PCT/BR2010/000290 BR2010000290W WO2011026206A1 WO 2011026206 A1 WO2011026206 A1 WO 2011026206A1 BR 2010000290 W BR2010000290 W BR 2010000290W WO 2011026206 A1 WO2011026206 A1 WO 2011026206A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- hpv
- protein
- immunogenic composition
- hsv
- nucleic acid
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/193—Colony stimulating factors [CSF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/208—IL-12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host
Definitions
- the present invention relates to synergistic immunogenic compositions comprising an expression vector encoding the HSV gD protein fused HPV E7 protein, an expression vector encoding a cytokine and a pharmaceutically acceptable carrier.
- the present invention also relates to isolated nucleic acid sequences encoding the HSV gD protein fused HPV E7 protein and comprise codons optimized for expression in mammalian cells, preferably human cells.
- the present invention also relates to expression vectors encoding nucleic acid sequences of the present invention.
- the present invention also relates to the use of one or more synergistic immunogenic compositions of the present invention in the manufacture of a vaccine for the prevention and / or treatment of papillomavirus-induced tumors in animals or humans.
- the present invention also relates to vaccines comprising one or more synergistic immunogenic compositions of the present invention.
- the present invention further relates to methods for preventing or treating papillomavirus-induced tumors comprising administering one or more synergistic immunogenic compositions of the present invention to animals or humans in need thereof.
- Cervical cancer is the third leading cause of cancer death in women worldwide causing 200,000 deaths per year (PISANI P. PARKIN DM, BRAY F. AND FERLAY J. (1999). cancers in 1990. Int. J. Cancer 83: 18-29).
- Epidemiological data show a clear relationship between human papilloma virus (HPV) infection and the development of cervical cancer, and the HPV genome can be detected in more than 99% of cases of this cancer. More than 100 types of HPV have been described, and about 20 have shown a propensity to infect anogenital tract tissues. Some types of HPV cause benign warts and lesions and are rarely found in invasive carcinomas, being called low-risk genotypes such as HPV-6 and HPV-11.
- HPV-16, HPV-18, HPV-31, HPV-33, and HPV-45 genotypes are often found in cervical tumor tissues and are called high-risk genotypes (WALBOOMERS, JM, JACOBS MV, MANOS MM).
- WALBOOMERS JM, JACOBS MV, MANOS MM.
- E6 and E7 proteins from high-risk genotypes are able to degrade p53 and inactivate pRb, cell cycle regulatory proteins, interfering with cell growth and multiplication (HOWLEY PM (1991) Role of the human papillomaviruses in human cancer. Cancer Res. 51: 5019s- 5022s).
- HPV-16 is found in 50% to 60% of cervical cancer cases and can be considered the main etiological agent of the disease (BOSCH FX, MANOS MM, MUNOZ N., SHERMAN M., JANSEN AM, PETO J., SCHIFFMAN MH, MORENO V., KURMAN R., SHAH KV (1995) Prevalence of human papillomavirus in cervical cancer: a worldwide perspective.International biological study on cervical cancer (IBSCC) Study Group J Natl Cancer Inst. 87 (11): 796-802).
- Therapeutic cancer vaccines appear as an alternative to surgical and radiotherapeutic processes.
- Several groups have described the development of vaccines that target HPV-16-induced cancer cells. Antigen-specific immunotherapy studies show that HPV-induced tumors can be controlled and sometimes eliminated by response-mediated activation. T cells specific for E7 and E6 proteins (LING M., KANAYAMA M., RODEN R., et al. (2000). Preventive and therapeutic vaccines for human papillomavirus-associated cervical cancers. J Biomed Sci. 7 (5): 341 -356).
- HPV-16 DNA vaccines that use the oncoprotein E7 gene in its native form induce low levels of CD8 + T cell activation and therefore do not protect animals against challenge using HPV-16 transformed cells (HUNG CF, MONIE A ., ALVAREZ RD, et al. (2007) DNA vaccines for cervical cancer: from bench to bedside Exp. Mol. Med. 39: 679-689 .; KANODIA S., DA SILVA DM, KAST WM (2008) Recent advances in strategies for immunotherapy of human papillomavirus-induced lesions Int J Cancer 15; 122 (2): 247-59).
- DNA vaccines capable of expressing HPV-16 oncoproteins E6 and E7 on the cell surface of transfected cells have recently been developed (LASARO, M. 0., DINIZ, M. 0., ARTURO, R., ERTL, H. C, FERREIRA, LCS, (2005) Anti-tumor DNA vaccines based on the expression of human papillomavirus-16 E6 / E7 genetically fused with the glycoprotein D from herpes simplex virus-1. Microbes and Infection 7: 1541-1550).
- oncoproteins E6 and E7 were genetically fused to herpes simplex virus type 1 (HSV-1) glycoprotein D (gD).
- HSV-1 herpes simplex virus type 1
- gD glycoprotein D
- the E7 protein was inserted into permissible sites near the C-terminal end of the herpes simplex virus type-1 (HSV-1) gD protein and its cloned vector gene suitable for expression in eukaryotic cells. This vector was named pgDE7.
- patent application O2008027394 which describes chimeric gD protein constructs and HPV-16 oncoproteins E5, E6 and E7 was either published in the form of DNA vaccine or viral vectors.
- GD-fused E7 constructs enhance immune responses against E7 protein, particularly CD8 + T lymphocyte mediated responses, and prophylactic protection to tumors expressing E7 protein.
- the strategy of cloning heterologous sequences in the gene encoding the gD protein used in this study was the same as that previously described by LASARO et al. 2005 (LASARO, MO, DINIZ, MO, ARTURO, R., ERTL, H.
- HSV-1 gD protein is an exposed surface protein anchored to the membrane of infected cells through a small sequence located near the C-terminal region.
- HPV-16 oncoproteins would be expressed in the extracellular medium, drastically reducing the oncogenic risks of transfected cells.
- the gD protein has the ability to increase the immunogenicity of E7, and other fused proteins, by competing with the BTLA (B and T lymphocyte attenuator) receptor for the Herpes virus entry receptor (HVEM) interaction site. mediator), reducing the co-inhibitory effects of BTLA on T and B lymphocytes (LASARO MO, TATSIS., HENSLEY SE, WHITBECK JC, LIN SW, RUX JJ, COHEREN GH, EISENBERG RJ, ERTL HC (2008) Targeting of antigen to the herpesvirus entry mediator augments primary adaptive immune responses Nat Med. 14 (2): 205-12).
- BTLA B and T lymphocyte attenuator
- HVEM Herpes virus entry receptor
- the vector expressing the gD-fused E7 protein under four-dose vaccine regimen, promoted the activation of E7-specific CD8 + T cells and preventively protected all animals prophylactically challenged with tumor cells.
- administration of the vaccine to animals that already contained tumor cells was able to regress tumors in 40% of the animals and slow the evolution of tumors in unprotected animals (LASARO, M. 0., DINIZ, MO, ARTURO, R., ERTL, H. C, FERREIRA, LCS, (2005) Anti-tumor DNA vaccines based on the expression of human papillomavirus-16 E6 / E7 oncoproteins genetically fused with the glycoprotein D from herpes simplex virus-1. Microbes and Infection 7: 1541-1550).
- HSV-1 glycoprotein D fused HPV-16 proteins E5, E6, and E7 was also described in patent application WO / 2008/027394. Published data involving this construct demonstrate that one dose of the vaccine generates complete prophylactic protection for tumor formation (LASARO MO, TATSIS N., HENSLEY SE, HITBECK JC, LIN SW, RUX JJ, WHERRY EJ, COHEN GH, EISENBERG RJ, ERTL HC (2008) Targeting of antigen to herpesvirus entry mediator augments primary adaptive immune responses Nat Med. 14 (2): 205-12).
- the vaccine only partially protects the tumor cell challenge in a therapeutic treatment regimen by keeping 70% of mice free of tumors following a 3-dose vaccination regimen (DINIZ, MO, LASARO, MO, ERTL, HC, FERREIRA, LCS (2010) Immune responses and therapeutic anti-tumor effects of an experimental DNA vaccine encoding the human papillomavirus type-16 (HPV-16) oncoproteins genetically fused to the herpes virus glycoprotein D. (gD) Clinical and Vaccine Immunology, Ahead of print ).
- pgDE7 and pgDE7E6E5 vaccine plasmids demonstrate anti-tumor therapeutic effect but are not effective in eradicating tumor cells in 100% of the tested animals.
- cytokines related to T cell activation or proliferation can be used, such as IL-2 (interleukin-2), IL-12. (interleukin-12) and GM-CSF (Granulocyte and macrophage colony stimulating factor). Plasmids encoding these cytokines are potent adjuvants capable of enhancing the humoral and cytotoxic immune response in animal models (BAROUCH, DH, A. CRAIU, J. KURODA, JE SCHMITZ, XX ZHENG, S., SANTRA, JD FROST, GR KRIVULKA, MA LIFTON, CL CRABBS , G.
- HEIDECKER (2007) Induction of specific immune responses by severe acute respiratory syndrome coronavirus spike DNA vaccine with or without interleukin-2 immunization using different vaccination routes in mice Clinical and vaccine immunol 14: 894-901; BL CHIANG, YL LEE, WK CHI, WC LIN, YT CHEN, and MH TAO. (1998) Development of Thl and Th2 populations and the nature of immune responses to hepatitis B virus DNA vaccines can be modulated by codelivery of various cytokine genes. J. Immunol 160: 1320-1329).
- interleukin-2 is a potent cytokine produced by activated T cells, capable of activating multiple compartments of the immune system and acting on clonal T cell proliferation (WALDMANN TA (2006) The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design (Nat Rev Immunol. 6: 595-601).
- IL-2 is one of the most widely used systemic adjuvants for peptide-based vaccines. Its clinical use has been approved by the FDA for the treatment of metastatic kidney cancer and malignant melanoma and is capable of inducing clinical responses in 15% of patients with these cancers (ROSENBERG SA, YANG JC, TOPALIAN SL, SCHWARTZENTRUBER DJ, WEBER JS, PARKINSON DR, et al (1994) Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA 271 (12): 907-13).
- Bovine interleukins 2 and 4 expressed in recombinant bovine herpesvirus 1 are biologically active secreted glycoproteins. J. Gene Virol. 77: 2231-2240), hepatitis C virus (GEISSLER, M., A. GESIEN, K. TOKUSHIGE, AND JR ANDS. (1997). Enhancement of cellular and humoral immune responses to hepatitis C core protein virus using DNA-based vaccines augmented with cytokine-expressing plasmids J.
- IL-2 has also been used to increase the HSV-1 glycoprotein D (gD) immune response used as an antigen in DNA vaccines (LI WR, NIU B, ANG JW, FENG ZJ, WANG DX. (2006) Coexpression of interleukin-2 enhancements to the immunization effect of a DNA vaccine expressing herpes simplex 1 glycoprotein D. Acta Virol. 50: 251-6).
- gD HSV-1 glycoprotein D
- Cytokine IL-12 also has a history of application in the treatment of tumors. Cytokine IL-12 has shown marked anti-tumor and anti-metastatic activity in numerous animal models (MAZZOLINI G, PRIETO J, MELERO I. (2003) Gene therapy of cancer with interleukin-12. Curr. Pharm. Des. 9 ( 24): 1981-91; RIEZEBOS-BRILMAN A, REGTSA J, CHEN M, WILSCHUTA J, DAEMENA T. (2009) Vaccine 27: 701-707). IL-12's ability to induce antigen-specific immune response is mainly related to its ability to polarize antigen-specific responses.
- Interleukin 12 induces stable priming for interferon gamma (IFN- gamma) production during differentiation of human T helper (Th) cells and transient IFN-gamma production in established Th2 cell clones J. Exp. Med. 179: 1273-1283; TSUNG K, MEKO JB, PEPLINSKI GR, TSUNG YL, NORTON J.A. (1997) IL-12 induces T helper-directed antitumor response (J. Immunol. 158: 3359-3365).
- IFN- gamma interferon gamma
- Th human T helper
- IL-12 also promotes maturation of cytotoxic and NK T cells and acts as a secondary signal to the antigen in increasing the population of effector and memory CD8 + T cells (WATFORD WT, MORIGUCHI M, MORINOBU A, O 'SHEA J J (2003) The biology of IL-12: coordinating innate and adaptive immune responses Cytokine Growth Factor Rev. 14: 361-368) (CURTSINGER JM, JOHNSON CM, MESCHER M F. (2003) CD8 T clonal cell expansion and development of eVector function require prolonged exposure to antigen, costimulation, and signal cytokine J.
- IL-12 is also able to facilitate antigen presentation by increasing expression of MHC class I and II molecules associated with IL-12's ability to promote IFN- ⁇ expression (WEISS JM, SUBLESKI JJ, WIGGINTON JM , WILTROUT R H. (2007) Expert Opin. Biol. Ther. 7; 1705-1721.)
- GM-CSF is able to initiate proliferation, differentiation and activation of macrophages, neutrophils and various antigen presenting cells (APCs), important activity in the therapeutic control of different tumors (AKIMOTO H, ABE J, TSUNODA R, AOYAGI M, HIRAKA AK , HAMADA H.
- GM-CSF When used in combination with DNA or protein vaccines, GM-CSF enhances antigen presentation by attracting dendritic cells to the vaccination site (TOUBAJI A, HILL S, TERABE M, QIAN J, FLOYD T, SIMPSON MR, BERZOFSKY JA, KHLEIF S. N. (2007) Vaccine 25: 5882-5891).
- Murine model assays demonstrate that GM-CSF induces specific T cell responses (AHLERS JD, DUNLOP N, ALLING D, NARA PL, BERZOFSKY J A.
- Cytokine-adjuvant steering of the immune response to HIV-1 vaccine constructs granulocyte-macrophage colony-stimulating factor and TNF-alpha synergize with IL-12 to enhance induction of cytotoxic T lymphocytes (J. Immunol. 158: 3947-3958).
- GM-CSF is used in clinical trials as an adjuvant in peptide-based vaccines (WEBER J, SONDAK VK, SCOTLAND R, PHILLIP R, WANG F, RUBIO TB, GROSHEN SG, GEE C, JEFFERY GG, SIAN S, LEE P. P.
- MAGE-A1-, MAGE-A10- , and gplOO-derived peptides are immunogenic when combined with granulocyte macrophage colony-stimulating factor and montanide ISA-51 adjuvant and administered as part of a multipeptide vaccine for melanoma (J. Immunol. 174: 3080-3086) and for treatments of various types. of tumors (SPITLER LE, GROSSBARD ML, ERNSTOFF MS, SILVER G, JACOBS M, HAYES FA, SOONG S J. (2000) Adjuvant therapy of stage III and IV ma lignant melanoma using granulocyte-macrophage colony-stimulating factor. J. Clin. Oncol.
- DNA vaccines Several clinical studies using DNA vaccines have failed to reproduce the immunological effects found in mice or even non-human primates. Although such assays demonstrate the safety of DNA vaccines, it has become apparent that modifications must be made to the formulations to increase immune responses in humans.
- One way to increase the immunogenicity of DNA vaccines involves the use of various adjuvants. Some of these adjuvants aim to improve the expression efficiency of coded antigens, either by methods that promote greater cell transfection efficiency or by optimizing expression through changes in target gene codons (KUTZLER MA AND WEINER D. (2008) DNA vaccines: ready for prime time (Nat See Genet. 9 (10): 776-88). In this latter approach the nucleotide sequences of the target genes are modified so that, during translation in the transfected cells, the most abundant types of carrier RNA for a given amino acid are employed resulting in increased antigen production and hence induction of higher specific immune responses.
- An important procedure to ensure the safety of human papillomavirus control vaccines is the modification of amino acids critical for the cancerous action of the E6 and particularly E7 oncoproteins.
- Such a procedure involves the modification of amino acids in the region between amino acids 19 to 26 of the E7 protein, whose residues lead to inactivation of pRB protein in epithelial cells with consequent loss of control of cell division and uncontrolled growth characteristic of papillomavirus associated neoplasms.
- the present invention aims to provide synergistic immunogenic compositions comprising an expression vector encoding the HSV gD protein fused HPV E7 protein, an expression vector encoding a cytokine and a pharmaceutically acceptable carrier.
- the present invention aims to provide synergistic immunogenic compositions comprising an expression vector encoding the HSV gD protein fused HPV E7 protein, an expression vector encoding a cytokine and a pharmaceutically acceptable carrier wherein the HPV is HPV-16, HPV-18, HPV-31, HPV-33 or HPV-45, HSV is HSV-1 or HSV-2, cytokine is IL-2, IL-12 or GM-CSF and the pharmaceutically acceptable carrier.
- the pharmaceutically acceptable carrier is PLGA saline, liposomes, lipid emulsions and / or microparticles.
- nucleic acid sequences encoding the HSV gD protein fused HPV E7 protein comprise codons optimized for expression in mammalian cells, preferably human cells in which the sequence is further mutated. prevent the interaction of HPV E7 protein with cellular protein Rb and where HPV is HPV-16, HPV-18, HPV-31, HPV-33, or HPV-45, HSV is HSV-1 or HSV-2.
- Another object of the present invention is methods of preventing or treating papillomavirus tumors comprising administering one or more synergistic immunogenic compositions of the present invention to animals or humans in need thereof.
- Figure 1 schematically shows the plasmid vectors used in the Examples of the present invention.
- Figure IA depicts the pgDE7 vector encoding the genetically fused HPV-16 E7 protein to the HSV-1 gD protein and contains an ampicillin resistance gene and Rous sarcoma virus-derived promoter for vaccine antigen expression.
- 1B is the pIL-2 vector encoding murine IL-2 cytokine.
- Figure 1C is represented the vector pVaxgDE7 which 1 encodes the genetically fused HPV-16 E7 protein to the HSV-1 gD protein and contains the kanamycin resistance gene and cytomegalovirus-derived promoter for vaccine antigen expression.
- Figure 1D shows the pgDE7h vector that has kanamycin resistance gene and encodes the genetically fused HPV-16 E7 protein to the HSV-1 gD protein and whose gene sequence has codons optimized for the expression system in human cells.
- Figure 2 shows the therapeutic protection assay of C57BL / 6 mice challenged with TC-1 tumor cells and immunized with a dose of each of the pgD, pIL-2 and pgDE7 vectors alone, or three doses of the pgDE7 vector, or one, two or three doses of immunogenic composition 1 (pgDE7 + pIL-2) (Protective effect).
- Figure 3 shows a therapeutic protection assay of C57BL / 6 mice challenged with TC-1 tumor cells and immunized with a 100 ⁇ g dose of the pIL-2 vector or a dose of the immunogenic composition 1 (pgDE7 + pIL-2) administered. at concentrations of 100 g, 50 ⁇ g, 25pg or 10 ⁇ g DNA / 100 ⁇ ⁇ ⁇ (Protective effect).
- Figure 4 shows a therapeutic protection assay of C57BL / 6 mice challenged with TC-1 tumor cells and immunized with either a 100pg dose of the pIL-2 vector or a dose of immunogenic composition 1 (pgDE7 + pIL-2) administered at the concentration. 50 ⁇ g DNA / ⁇ ⁇ ⁇ administered on the same day (day 0), 3, 7, 10 or 14 days after challenge (Protective effect).
- Figure 5 shows tumor growth in C57BL / 6 mice challenged with TC-1 tumor cells and immunized with a dose of each of the pIL-2 and pDE7 vectors alone or with a dose of the immunogenic composition 1 (pgDE7 + pIL-2).
- Figure 6 shows a therapeutic protection trial. 1 of C57BL / 6 mice challenged with TC-1 tumor cells and immunized with a dose of each of the pIL-2 and pVaxgDE7 vectors alone or with a dose of immunogenic composition 2 (pVaxgDE7 + pIL-2) at 50pg DNA concentration / 100 ⁇ , / dose administered 3 days after challenge (Protective effect).
- Figure 7 shows a therapeutic protection assay of C57BL / 6 mice challenged with TC-1 tumor cells and immunized with a dose of pIL-2, pgDE7 or pgDE7h vectors (alone at 50 ⁇ g DNA / 100 L / dose administered 3). days after challenge (Protective effect).
- Figure 8 shows the minimum amount of pgDE7h vector required for maximal anti-tumor therapeutic efficacy of immunogenic composition 3 (pgDE7h + pIL-2).
- a therapeutic protection assay of C57BL / 6 mice challenged with TC-1 tumor cells and immunized with either a dose of either pIL-2 and pgDE7h alone or a dose of immunogenic composition 3 (pgDE7h + pIL-2) is shown.
- various DNA / dose concentrations administered 3 days after challenge is shown.
- Animals were immunized with a dose of 50pg DNA / 100 L / dose pIL-2 vector, or pgDE7h vector, or immunogenic composition 3 (pgDE7h + pIL-2) and 25 ⁇ g DNA / 100 L / dose pgDE7h vector or immunogenic composition 3 (pgDE7h + pIL-2) (Fig. 8A), or a dose of 10vq DNA / 100 L / dose of pgDE7h vector or immunogenic composition 3 (pgDE7h + pIL-2) or a dose 5 g DNA / 100 L / dose of the pgDE7h vector or immunogenic composition 3 (pgDE7h + pIL-2) (Fig. 8B).
- the present invention provides synergistic immunogenic compositions for prevention and treatment of papillomavirus tumors in animals and humans.
- the synergistic immunogenic compositions of the present invention comprise an expression vector encoding the HSV gD protein fused HPV E7 protein, a cytokine encoding expression vector, and a pharmaceutically acceptable carrier.
- the expression vector encoding the HPV E7 protein fused to the HSV gD protein encodes an HPV-16, HPV-18, HPV-31, HPV-33 or HPV-45 E7 sequence. Even more preferably, the E7 sequence is from HPV-16.
- the expression vector encoding the HPV E7 protein fused to the HSV gD protein encodes an HSV-1 or HSV-2 gD sequence. Even more preferably, the gD sequence is from HSV-1.
- the expression vector encoding the HSV gD protein fused HPV E7 protein encodes a nucleic acid sequence whose codons are optimized for expression in mammalian cells. Even more preferably codons are optimized for expression in human cells.
- the expression vector encoding the HPV gD protein fused to the HSV gD protein encodes a nucleic acid sequence whose codons are optimized for expression in mammalian or human cells and whose sequence is mutated to prevent interaction of the E7 protein. of HPV with cellular protein Rb.
- sequence is mutated at positions 24 and 26 of E7.
- E7 positions 24 and 26 are mutated to a glycine.
- the E7 protein coding sequence could be readily exchanged for sequences coding for other oncoproteins encoded by another human or animal papillomavirus, such as the E5, E6 and E2 proteins.
- the expression vector encoding a cytokine encodes IL-2, IL-12, IL-15, IL-18 or GM-CSF as well as other cytokines that may act synergistically on the antitumor effects of the composition. immunogenic.
- the expression vector encoding a cytokine encodes IL-2.
- the cytokine IL-2 may be human or other mammalian species.
- the immunogenic compositions of the present invention may comprise purified proteins derived from the sequences encoded by the expression vectors encoding the HSV gD protein fused HPV protein and the cytokine encoding expression vector of interest as described in the present invention. .
- synergistic immunogenic compositions of the present invention are prepared using good laboratory practices and good manufacturing practices, free from endotoxins and suitable for use in preclinical and / or clinical testing.
- the synergistic immunogenic compositions of the present invention may be prepared using various pharmaceutically acceptable carriers.
- the term "pharmaceutically acceptable” means a non-toxic, inert solid, semi-solid liquid excipient, diluent, auxiliary formulation of any kind, or simply a sterile aqueous medium such as saline.
- Examples of materials that may serve as pharmaceutically acceptable carriers are sugars such as lactose, glucose and sucrose, starches such as cornstarch and potato starch, cellulose and derivatives thereof such as sodium carboxymethylcellulose, ethyl cellulose and cellulose acetate, cyclodextrin; oils such as peanut oil, cottonseed oil, sunflower oil, sesame oil, olive oil, corn and soybean oil; glycols such as propylene glycol, polyols such as glycerin glycol, sorbitol, mannitol and polyethylene; esters such as ethyl laurate, ethyl oleate, agar; buffering agents such as aluminum hydroxide and magnesium hydroxide; alginic acid; pyrogen free water; isotonic saline, Ringer's solution; ethyl alcohol and phosphate buffer solutions as well as other compatible non-toxic substances used in pharmaceutical formulations.
- sugars such as lactose, glucose and sucrose, star
- the carrier is saline.
- the carrier further comprises sustained or controlled release non-viral delivery systems such as liposomes, lipid emulsions, biodegradable particles consisting of glycolic acid poly lactate (PLGA) and chitosan, as well as the use of other adjuvants directed to increased therapeutic and preventive efficacy of the composition.
- sustained or controlled release non-viral delivery systems such as liposomes, lipid emulsions, biodegradable particles consisting of glycolic acid poly lactate (PLGA) and chitosan, as well as the use of other adjuvants directed to increased therapeutic and preventive efficacy of the composition.
- PLGA microspheres composed of lactic and glycolic acid polymers (PLGA) have the potential to act as phagocytic cell transfection mediators such as macrophages and dendritic cells, and protect DNA against biological degradation by endonucleases by increasing the transfection rate.
- PLGA microspheres are composed of biodegradable and biocompatible material, are harmless, are phagocytized by APCs cells and are already approved by the US FDA for human use.
- PLGA microspheres have great applicability for DNA vaccine vectorization as they can be designed to release amounts of the plasmid continuously and / or rapidly.
- the rate of hydrolysis of such polymers depends on: their chemical composition, the proportion of monomers; chain size and particle size and degradation times ranging from 2 weeks to 24 months can be obtained.
- the combination of pore diffusion and erosion of the polymeric matrix allows to control the release rate of encapsulated DNA or antigen in the microspheres. This property allowed the group to create the single-dose vaccine concept where the formulation composed of microspheres of different size, porosity and polymeric composition released E7 and IL-2 containing plasmids at time intervals that would mimic the booster doses of a single dose. vaccine.
- Other advantages of using these systems for plasmids E7 and IL-2 are: easy administration; high stability as they are lyophilized and can be reconstituted just prior to administration.
- Liposomes are aggregates of phospholipids in bilayer structures containing a central aqueous volume surrounded by one or more concentric lamellae, forming unilamellar or multilamellar particles, with diameters of the order of tens of nanometers to tens of microns.
- liposomes encapsulate part of the aqueous medium in which they are dispersed.
- the bilayer is capable of accommodating hydrophobic molecules and behaves as a semipermeable membrane with respect to the encapsulated material in the aqueous volume of the vesicles.
- liposomes can be cationic, anionic or neutral. However, regarding the use of negatively charged biomolecules (such as DNA and some proteins), encapsulation of these molecules into cationic liposomes is more efficient due to the electrostatic liposome-biomolecule interaction.
- Cationic liposomes are commonly used to carry negative molecules such as DNA and facilitate their input to the cell.
- Such liposomes may contain only cationic lipid or a mixture with neutral lipids such as La-dioleoyl phosphatidylethanolamine (DOPE) and cholesterol. Initially stearylamine was used as a cationic lipid, however, the studies did not continue due to its cytotoxicity.
- DOPE La-dioleoyl phosphatidylethanolamine
- quaternary ammonium salts such as 1,2-dioleoyl-3-trimethylammonium propane (DOTAP) and dimethyldioctadecyl ammonium bromide
- DOTAP 1,2-dioleoyl-3-trimethylammonium propane
- dimethyldioctadecyl ammonium bromide dimethyldioctadecyl ammonium bromide
- liposome-encapsulated DNA vaccines administered the same route protect the biomolecule from nucleases and proteases and are preferably captured by antigen presenting cells, enhancing the immune response. It is reported that the main pathway of cell entry is endocytosis, and the least usual (only 2%), by fusing the liposome with the cell membrane and releasing its contents directly to the cytosol (TROMBONE APF, SILVA CL, ALMEIDA LP , ROSADA RS, LIMA KM, OLIVER C, JAMUR MC AND RABBIT CASTLE A (2007) .Tissue distribution of DNA-Hsp65 / TDM-loaded PLGA microspheres and uptake by phagocytic cells.
- DRV Dehydrated-Rehydrated Vesicles
- compositions of the present invention may be administered by any biologically acceptable method, i.e. any embodiment that can produce effective levels of the active compounds without causing clinically undesirable adverse effects.
- modes of administration include oral, rectal, sublingual, topical, nasal, transdermal or parenteral routes.
- parenteral includes subcutaneous, intravenous, epidural, irrigation, intramuscular, release, or infusion pumps. Particularly in this invention the intramuscular route is referred to for administration of the compositions claimed herein.
- Doses may be applied in amounts ranging from 0.1 pg DNA to 100 pg DNA per dose in the mouse model, and in humans or other mammalian species with doses ranging from 0.1 pg DNA to 5 ⁇ g. mg DNA per dose.
- the proposed immunogenic composition is based on the combination of two vectors (one encoding cytokine and the other encoding the hybrid protein gD / E7).
- This novel composition has unexpected and enhanced immunological and anti-tumor properties that provide preventive and therapeutic protection against papillomavirus tumors.
- the combination of the two vectors revealed unexpected synergistic properties that confer unique antitumor effects to the immunogenic compositions of the present invention that cannot be achieved with formulations based only on vectors expressing the HPV fusion protein to the HSV gD protein already described in the prior art.
- HSV gD protein fused HPV E7 protein comprising codons optimized for expression in mammalian cells, preferably human cells.
- the present invention also provides isolated nucleic acid sequences encoding the HSV gD protein fused HPV E7 protein and comprise codons optimized for expression in mammalian cells, preferably human cells.
- This artificial gene sequence promotes increased immunogenicity of the E7 and gD proteins and represents a fundamental step towards enhancing the preventive and therapeutic efficacy of the immunogenic compositions of the present invention.
- this sequence may be further mutated to prevent the interaction of the HPV E7 protein with the pRb protein involved in controlling the cell multiplication cycle.
- Such changes aim to eliminate any residual oncogenic activity of the E7 protein, preventing chimeric protein expression from interfering with the cell cycle of transfected cells and enhancing the safety of the nucleic acid sequence and compositions comprising it.
- mutations in the E7 protein coding sequence are preferably at the amino acids of positions 24 and 26 of E7. Even more preferably the E7 position 24 cysteine is mutated to a glycine and the E7 position 26 glutamic acid is mutated to a glycine.
- the isolated nucleic acid sequences encoding the HSV gD protein fused HPV E7 protein and comprising codons optimized for expression in mammalian cells encode HPV-16 E7 protein, HPV-18, HPV-31, HPV-33 and HPV-45. Even more preferably the isolated nucleic acid sequences encode the HPV-16 E7 protein.
- the isolated nucleic acid sequences encoding the HSV gD protein fused HPV E7 protein and comprising codons optimized for expression in mammalian cells encode HSV-1 or HSV-2 gD. Even more preferably the isolated nucleic acid sequences encode the HSV-1 gD protein.
- the present invention further provides expression vectors encoding nucleic acid sequences of the present invention.
- Another aspect of the present invention is the use of one or more synergistic immunogenic compositions of the present invention in the manufacture of a vaccine for the prevention, control or treatment of papillomavirus-induced tumors in animals or humans.
- a further aspect of the present invention is methods of preventing papillomavirus-induced tumors comprising administering one or more animal or human synergistic immunogenic compositions of the present invention in need thereof.
- Further aspect of the present invention is methods of controlling or treating papillomavirus-induced tumors comprising administering one or more synergistic immunogenic compositions of the present invention to animals or humans in need thereof.
- the animals are pets (dogs, cats) or animals of agricultural interest, such as cattle, horses, pigs, goats and sheep.
- Example 1 Construction of the nucleic acid sequence encoding the HPV-16 E7 protein fused to the HSV-1 gD protein with codons optimized for expression in mammalian cells.
- NotI (6 first bases) and BglII (6 last bases) restriction enzyme cloning sites were inserted to enable cloning of the sequence into plasmid pUMVC3, marketed by Aldevron, and licensed for clinical trials.
- the murine interleukin 2 (IL-2) gene was PCR amplified and cloned into the pcDNA3.1 vector (Invitrogen).
- the pgDE7 vector was constructed by amplifying the E7 protein gene from the entire HPV-16 genome using specific primers designed based on the GeneBank deposited sequence (GI: 9627100) and including sites for the Apal enzyme in the E7 primers.
- Plasmid pRE4 containing the HSV-1 glycoprotein D gene kindly provided by Dr. G. Cohen of the University of Pennsylvania, was used for the cloning of the gD-fused E7 gene.
- plasmid pgDE7h SEQ. ID. 2
- gDE7h SEQ. ID. 1
- HSV-1 HSV-1 with the codon sequence optimized for expression in mammalian cells, particularly humans, at the N1 and ⁇ coRV sites of plasmid pUMVC3.
- the electrocompetent cells used for transformation with the pRE4 vector were Escherichia coli JM 110 bacteria. Restriction, binding, agarose gel electrophoresis, DNA fragment purification, and electroporation treatments followed routine laboratory procedures. All plasmids were propagated in Escherichia coli DH5a in LB medium supplemented with ampicillin (100 ⁇ g / mL) or kanamycin (100 ⁇ g / mL) and purified by double cesium chloride density gradient followed by ethanol precipitation and resuspension in sterile water.
- the DNA content of the samples was determined by spectrophotometer at 260nm and confirmed by visual inspection on ethidium bromide stained 1% agarose gel using DNA fragments of known concentrations (Invitrogen).
- the plasmids were kept at -20 ° C until the time of use, when the concentration will be adjusted to l ⁇ g / ⁇ L in PBS.
- pgDE7 pgD gDE7 (carries the HPV-16 E7 gene fused to the HSV-1 gD gene)
- pVAXgDE7 pVax gDE7 (carries the HPV-16 E7 gene fused to the HSV-1 gD gene)
- pgDE7h pUMVC3 gDE7h load the synthetic gene encoding the HPV-16 E7 gene fused to the HSV-1 gD gene and has codon sequence optimized for expression in mammalian cells
- the immunogenic compositions of the present invention were prepared using the plamids described in Table 1 above.
- compositions with increasing amounts of DNA were prepared.
- the TC-1 tumor cell line is derived from primary C57B1 / 6 pulmonary epithelial cells transformed with v-Has-ras and the HPV-16 E6 and E7 genes (kindly provided by Dr. TC Wu, Johns Hopkins University , USA).
- TC-1 cells were cultured in MS medium supplemented with 2mM L-glutamine, 1mM sodium pyruvate, 2mM nonessential amino acids, 10mM HEPES buffer, 50 U / mL penicillin / streptomycin, 10% fetal bovine serum (SFB) and maintained at 37 ° C and 5% CO 2 .
- MS medium supplemented with 2mM L-glutamine, 1mM sodium pyruvate, 2mM nonessential amino acids, 10mM HEPES buffer, 50 U / mL penicillin / streptomycin, 10% fetal bovine serum (SFB) and maintained at 37 ° C and 5% CO 2 .
- FFB fetal bovine serum
- mice were inoculated subcutaneously with TC-1 tumor cells prepared as described in
- Example 4 at a concentration of 5x10 10 cells / animal. The cells were resuspended in 100 ⁇ of serum free medium and inoculated in a dorsolateral region of the animal. To determine the effect of immunogenic compositions on regression of established tumors, mice were challenged with TC-1 cells and eight hours later the vaccine protocol was initiated.
- the immunogenic compositions described in Example 3 were administered intramuscularly. Groups of 5-10 animals were vaccinated with the immunogenic compositions or intramuscular DNA vaccines. The doses of each composition (10 ⁇ g to 100 ⁇ g of DNA diluted in 100 L PBS) were inoculated into the anterior tibial muscle of each paw (50 ⁇ per paw).
- Animals challenged with TC-1 tumor cells were immunized with one dose of each of the pgD, pIL-2 and pgDE7 vectors alone, or three doses of the pgDE7 vector, or one, two or three doses of immunogenic composition 1 (pgDE7 + pIL). -2) administered intramuscularly at a dose concentration of 100 ⁇ g ⁇ / ⁇ , ⁇ .
- Vaccine protocols began on the same day of the TC-1 tumor cell challenge.
- the compositions comprising the pgD and pIL-2 vectors alone were not able to keep mice free of tumors.
- the pgDE7 vector alone generated 70% protection after three doses and no significant protection with one or two doses.
- immunogenic composition 1 comprising pgDE7 and pIL-2 vectors was able to protect 100% of mice from tumor development by inoculating one, two or three doses of the composition revealing that the combination of both vectors into a single immunogenic formulation has an unexpected synergistic effect (Figure 2).
- mice challenged with TC-1 tumor cells were immunized with either a 100 ⁇ g dose of pIL-2 vector or a dose of pharmaceutical composition 1 (pgDE7 and pIL-2). administered in the amount of 100pg, 50 ⁇ g, 25 ⁇ or 10pg DNA / 100 ⁇ L / dose.
- Vaccine regimens began on the same day of the TC-1 tumor cell challenge.
- the immunogenic pharmaceutical composition comprising the vectors pgDE7 and pIL-2 was able to protect 100% of mice from single dose tumor development by inoculating 100 ⁇ g, 50g and 25pg 100 / 100 ⁇ ] _, / ⁇ 3 ⁇ . Inoculation of 10 ⁇ g of protected 50% of mice from tumor development and the pIL-2 vector alone was unable to keep mice free of tumors (Figure 3).
- mice challenged with TC-1 tumor cells were immunized with either a 100 g dose of the pIL-2 vector or a dose of immunogenic composition 1 (pgDE7 + pIL-2) administered at a concentration of 50 ⁇ g DNA / 100 ⁇ / dose administered therein. day (day 0) or 3, 7, 10, or 14 days after the challenge.
- the immunogenic composition comprising the pgDE7 and pIL-2 vectors was able to protect 100% of the single dose mice by inoculating 50 ⁇ g DNA / dose when the vaccine was administered on the same day or up to 3 days after challenge.
- the pharmaceutical composition was inoculated on days 7, 10 and 14, the protection values obtained were reduced to 60%, 40% and 0% of the treated mice, respectively.
- the pIL-2 vector alone was not able to confer any anti-tumor protection to the mice ( Figure 4).
- the immunogenic composition comprising the pgDE7 and pIL-2 vectors protected all mice and no tumor development was observed.
- the pIL-2 vector alone was not able to keep mice free of tumors. In this case the tumors reached sizes larger than 1 cm in diameter 32 days after challenge. Non-immunized animals reached tumors of the same size approximately after 36 days. While mice immunized with a single dose of the pgDE7 vector developed tumors with an average size of 0.35 cm at the end of the observation period of the experiment (42 days).
- Animals challenged with TC-1 tumor cells were immunized with a dose of each of the pIL-2 and pVaxgDE7 vectors alone or with a dose of immunogenic composition 2 (pVaxgDE7 + pIL-2) at a concentration of 50 ⁇ g DNA / 100 L / dose administered 3 days after challenge.
- the composition The immunogenic immunoglobulin comprising pVaxgDE7 and pIL-2 vectors was able to protect 100% of mice from single dose tumor development. Under the same conditions, vectors pIL-2 and pVaxgDE7 alone were not able to keep mice free of tumors. These results demonstrate that the pgDE7 and pVaxgDE7 vectors have similar anti-tumor efficacy. This result shows that the pVaxgDE7 vector has the same anti-tumor effect as the pgDE7 vector when combined with the pIL-2 vector ( Figure 6).
- Plasmid pgDE7h which comprises the artificial sequence of HPV-16 E7 and HSV-1 gD genes optimized for better expression in human cells, protected 100% of mice against the development of single-dose tumors while in them Under experimental conditions, plasmid pgDE7 and vector pIL-2 alone were unable to keep mice free of tumors.
- the pgDE7h vector When administered alone, the pgDE7h vector was able to protect all animals inoculated with tumor cells at a concentration of only 50 g DNA / 100pL / dose. At a concentration of 25 g DNA / 100pL / dose only 40% of mice treated with 25 ⁇ q of the vector were tumor free. Administration of 10 q or 5 g DNA / 100pL / dose of plasmid pgDE7h was not able to maintain tumor free mice. On the other hand, immunogenic composition 3 (pgDE7h + pIL-2) was able to protect all mice from tumor development when administered at the same concentrations of (50pg, 25g and 10pg DNA / 100pL / dose).
- immunogenic composition 3 (pgDE7h + pIL-2) was able to protect 80% of the animals against tumor development.
- the pIL-2 vector alone was not able to keep mice free of tumors at different concentrations tested.
- compositions 1 pgDE7 + IL-2
- 2 pVAXgDE7 + pIL-2
- 3 pgDE7h + pIL-2
- TC-1 administered intramuscularly in amounts ranging from 25 ⁇ g to 100 ⁇ g DNA / 100 L / dose.
- compositions as well as other formulations comprising simultaneously plasmids expressing HSV gD protein fused HPV E7 protein and cytokine encoding plasmids, represent a unique anti-tumor therapeutic strategy.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- General Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Plant Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BR112012004928-3A BR112012004928B1 (pt) | 2009-09-04 | 2010-09-06 | Sequência de ácido nucleico isolada, vetor de expressão,composição imunogênica sinérgica que compreende um vetor de expressão que codifica a proteína e7 do vírus do papiloma humano (hpv) fusionada à proteína gd do vírus herpes humano tipo 1 (hsv-1) e um vetor de expressão que codifica uma citocina, seus usos e vacina contendo composição imunogênica sinérgica |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BRPI0904880-4A BRPI0904880A2 (pt) | 2009-09-04 | 2009-09-04 | composição farmacêutica contendo um plasmìdeo que expressa a oncoproteìna e7 de hpv-16 fusionada a gd do hsv-1 co-administrado com um plasmìdeo que expressa a il-2 e o seu uso no controle de tumores induzidos por hpv-16 |
BRPI0904880-4 | 2009-09-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2011026206A1 true WO2011026206A1 (pt) | 2011-03-10 |
Family
ID=43648795
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/BR2010/000290 WO2011026206A1 (pt) | 2009-09-04 | 2010-09-06 | SEQÜÊNCIA DE ÁCIDO NUCLÉICO ISOLADA, VETOR DE EXPRESSÃO, COMPOSIÇÃO IMUNOGÊNICA SINÉRGICA QUE COMPREENDE UM VETOR DE EXPRESSÃO QUE CODIFICA A PROTEÍNA E7 DO VÍRUS DO PAPILOMA HUMANO (HPV) FUSIONADA À PROTEÍNA gD DO VÍRUS HERPES HUMANO TIPO 1 (HSV-1) E UM VETOR DE EXPRESSÃO QUE CODIFICA UMA CITOCINA E SEUS USOS |
Country Status (2)
Country | Link |
---|---|
BR (2) | BRPI0904880A2 (pt) |
WO (1) | WO2011026206A1 (pt) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114146213A (zh) * | 2021-12-06 | 2022-03-08 | 广西博生生物科技有限公司 | 一种复合卵黄球γ蛋白的凝胶敷料及其制备方法与应用 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001051516A2 (de) * | 2000-01-13 | 2001-07-19 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Fusionsproteine zur stimulierung von cytotoxischen t-zellen |
US20040028693A1 (en) * | 2000-08-01 | 2004-02-12 | Wu Tzyy Choou | Molecular vaccine linking intercellular spreading protein to an antigen |
WO2008027394A2 (en) * | 2006-08-28 | 2008-03-06 | The Wistar Institute Of Anatomy And Biology | Constructs for enhancing immune responses |
-
2009
- 2009-09-04 BR BRPI0904880-4A patent/BRPI0904880A2/pt not_active IP Right Cessation
-
2010
- 2010-09-06 BR BR112012004928-3A patent/BR112012004928B1/pt active IP Right Grant
- 2010-09-06 WO PCT/BR2010/000290 patent/WO2011026206A1/pt active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001051516A2 (de) * | 2000-01-13 | 2001-07-19 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Fusionsproteine zur stimulierung von cytotoxischen t-zellen |
US20040028693A1 (en) * | 2000-08-01 | 2004-02-12 | Wu Tzyy Choou | Molecular vaccine linking intercellular spreading protein to an antigen |
WO2008027394A2 (en) * | 2006-08-28 | 2008-03-06 | The Wistar Institute Of Anatomy And Biology | Constructs for enhancing immune responses |
Non-Patent Citations (3)
Title |
---|
HINUMA, S. ET AL.: "A novel strategy for converting recombinant viral protein into high immunogenic antigen.", FEBS LETTERS, vol. 288, no. 1-2, August 1991 (1991-08-01), pages 138 - 142 * |
LASARO, M.O. ET AL.: "Anti-tumor DNA vaccines based on the expression of human papillomavirus-16 E6/E7 oncoproteins genetically fuse with the glycoprotein D from herpes simplex virus- 1.", MICROBES AND INFECTION, vol. 7, no. 15, December 2005 (2005-12-01), pages 1541 - 1550 * |
SCHENCK, S. ET AL.: "Expression of human papilloma virus type 16 antigens, specific targeting as well as formation of virus-like particles by HSV amplicon vectors.", VIRUS GENES., vol. 37, no. 2, October 2008 (2008-10-01), pages 131 - 143 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114146213A (zh) * | 2021-12-06 | 2022-03-08 | 广西博生生物科技有限公司 | 一种复合卵黄球γ蛋白的凝胶敷料及其制备方法与应用 |
Also Published As
Publication number | Publication date |
---|---|
BR112012004928B1 (pt) | 2023-01-31 |
BRPI0904880A2 (pt) | 2011-05-17 |
BR112012004928A2 (pt) | 2020-08-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2759785T3 (es) | Adenovirus que expresan antígenos oncógenos heterólogos | |
Lin et al. | Therapeutic hpv DNA vaccines | |
CN109331176B (zh) | 用于免疫治疗的rna制剂 | |
KR102351555B1 (ko) | Hpv 및 관련 질환용 면역 증강 치료 백신 | |
Chen et al. | A simple but effective cancer vaccine consisting of an antigen and a cationic lipid | |
US9095537B2 (en) | Therapy of cancer based on targeting adaptive, innate and/or regulatory component of the immune response | |
Cui et al. | Liposome-polycation-DNA (LPD) particle as a carrier and adjuvant for protein-based vaccines: therapeutic effect against cervical cancer | |
JP2016516723A (ja) | ガンワクチン及びそれを用いた治療方法 | |
TW201729829A (zh) | 包含融合有免疫球蛋白Fc之介白素-7的用於預防或治療人類乳頭狀瘤病毒相關疾病的藥學組成物 | |
KR20190073416A (ko) | 신규한 hpv16 hla-비제한적 t-세포 백신, 조성물 및 이의 사용 방법 | |
ES2163795T5 (es) | Composicion farmaceutica contra los tumores e infecciones por papilomavirus. | |
ES2667476T3 (es) | Método para invertir la supresión inmunitaria de células de Langerhans | |
Bolhassani et al. | Modified DCs and MSCs with HPV E7 antigen and small Hsps: Which one is the most potent strategy for eradication of tumors? | |
JP2024036364A (ja) | I型インターフェロン遺伝子を刺激するための方法及びカチオン性脂質を含む組成物 | |
Mohit et al. | Immunomodulatory effects of IP-10 chemokine along with PEI600-Tat delivery system in DNA vaccination against HPV infections | |
KR20190038480A (ko) | 프라임:부스트 병용 요법제 | |
TW201938793A (zh) | 一種新型疫苗佐劑 | |
Viehl et al. | A Tat Fusion Protein–Based Tumor Vaccine for Breast Cancer | |
KR20190092371A (ko) | 섬유아세포 활성화 단백질을 표적화하는 최적화된 합성 컨센서스 면역원성 조성물 | |
US11608362B2 (en) | Hepatitis B vaccines and uses of the same | |
KR100904844B1 (ko) | 인유두종 바이러스(hpv)유전자를 포함하는자궁경부암의 치료 또는 예방용 dna 백신 | |
ES2634256T3 (es) | Composiciones innovadoras y usos de las mismas | |
US20140199347A1 (en) | Adjuvant compositions with 4-1bbl | |
WO2011026206A1 (pt) | SEQÜÊNCIA DE ÁCIDO NUCLÉICO ISOLADA, VETOR DE EXPRESSÃO, COMPOSIÇÃO IMUNOGÊNICA SINÉRGICA QUE COMPREENDE UM VETOR DE EXPRESSÃO QUE CODIFICA A PROTEÍNA E7 DO VÍRUS DO PAPILOMA HUMANO (HPV) FUSIONADA À PROTEÍNA gD DO VÍRUS HERPES HUMANO TIPO 1 (HSV-1) E UM VETOR DE EXPRESSÃO QUE CODIFICA UMA CITOCINA E SEUS USOS | |
JP2023554155A (ja) | 癌を治療するための治療用rna |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10813183 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 10813183 Country of ref document: EP Kind code of ref document: A1 |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112012004928 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 112012004928 Country of ref document: BR Kind code of ref document: A2 Effective date: 20120305 |